UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 23, 2012
Omni Bio Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
|
Colorado
|
000-52530
|
20-8097969
|
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
5350 South Roslyn, Suite 430, Greenwood Village, CO
|
80111
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(303) 867-3415
|
|
|
(Registrant’s telephone number, including area code)
|
|
|
(Former name or former address, if changed since last report)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On August 23, 2012, James D. Crapo resigned as a director and chief executive officer of Omni Bio Pharmaceutical, Inc. (the “Company”) effective August 31, 2012. On August 27, 2012, the Company’s board of directors appointed Steven M. Bathgate, a director, to serve as interim chief executive officer of the Company beginning August 31, 2012 until a successor is appointed.
See the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2012 for Mr. Bathgate's biographical information and a description of certain related person transactions between the Company and affiliates of Mr. Bathgate.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Omni Bio Pharmaceutical, Inc.
|
|||
|
Date: August 27, 2012
|
|||
|
By:
|
/s/ Robert C. Ogden | ||
|
Robert C. Ogden
Chief Financial Officer
|
|||